AR084857A1 - Derivados de azetidina utiles para el tratamiento de enfermedades metabolicas e inflamatorias - Google Patents
Derivados de azetidina utiles para el tratamiento de enfermedades metabolicas e inflamatoriasInfo
- Publication number
- AR084857A1 AR084857A1 ARP120100129A ARP120100129A AR084857A1 AR 084857 A1 AR084857 A1 AR 084857A1 AR P120100129 A ARP120100129 A AR P120100129A AR P120100129 A ARP120100129 A AR P120100129A AR 084857 A1 AR084857 A1 AR 084857A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- halo
- independently selected
- alkoxy
- Prior art date
Links
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical class C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
- 230000002503 metabolic effect Effects 0.000 title 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 15
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 125000005309 thioalkoxy group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Estos compuestos pueden ser preparados como una composición farmacéutica, y pueden ser empleados para la prevención y tratamiento de una variedad de afecciones en mamíferos incluyendo seres humanos, incluyendo a modo de ejemplo no limitativo afecciones inflamatorias, enfermedades infecciosas, enfermedades autoinmunes, enfermedades que involucran el deterioro de funciones de células inmunes, enfermedades cardiometabólicas, y/o enfermedades proliferativas.Reivindicación 1: Un compuesto de acuerdo con la fórmula (1) donde L1 es un enlace simple, o CRaRb; L2 es un enlace simple, O, NRe o CRcRd; cada uno de Ra, Rb, Rc, y Rd es independientemente seleccionado entre H, y alquilo C1-4; o Ra y Rb en conjunto con el carbono al cual están unidos pueden formar un cicloalquilo C3-7; o Rc y Rd en conjunto con el carbono al cual están unidos pueden formar un cicloalquilo C3-7; Re es alquilo C1-4; Y es alquilo C1-4 opcionalmente sustituido con uno o más grupos seleccionados independientemente entre flúor, OH, y fenilo (opcionalmente sustituido con uno o más grupos seleccionados independientemente entre alquilo C1-4 (opcionalmente sustituido con uno o más halo), alcoxi C1-4, halo y ciano), o alquenilo C1-4 que comprende 1 doble enlace; cada uno de Cy1 y Cy2 es independientemente arilo C6-10, o heteroarilo de 5 - 10 miembros; cada R1 es independientemente seleccionado entre halo, alquilo C1-4 (opcionalmente sustituido con uno o más halo), y alcoxi C1-4 (opcionalmente sustituido con uno o más halo); R2 es: H; alquilo C1-4 opcionalmente sustituido con uno o más grupos R2a independientemente seleccionados; cicloalquilo C3-7 opcionalmente sustituido con uno o más grupos R2a independientemente seleccionados; R2a es halo, alcoxi C1-6, OH, C(=O)R4, S(O)2R4, CN, NHC(=O)R5, NHSO2R5, heterocicloalquilo de 5 - 7 miembros (opcionalmente sustituido con uno o más grupos seleccionados independientemente entre alquilo C1-4, y oxo), o heteroarilo de 5 - 6 miembros (opcionalmente sustituido con uno o más grupos seleccionados independientemente entre halo, OH, alcoxi C1-4 y alquilo C1-4); R3 se selecciona entre halo, alquilo C1-6 (opcionalmente sustituido con uno o más halo), alcoxi C1-6 (opcionalmente sustituido con uno o más halo, o fenilo), tioalcoxi C1-6, fenilo (opcionalmente sustituido con uno o más grupos seleccionados independientemente entre halo, alquilo C1-4 (opcionalmente sustituido con uno o más halo), alcoxi C1-4, C(=O)-alcoxi C1-4 y CN); R4 es OH, alcoxi C1-6, heterocicloalquilo de 5 - 7 miembros N-ligado (opcionalmente sustituido con uno o más grupos seleccionados independientemente entre alquilo C1-6, y oxo), NR4aR4b, o NHSO2R4c; cada uno de R4a y R4b es independientemente H, alquilo C1-4 (opcionalmente sustituido con fenilo (opcionalmente sustituido con uno o más grupos seleccionados independientemente entre halo, CN, alquilo C1-6, y alcoxi C1-6)), o cicloalquilo C3-7; R4c es fenilo, heteroarilo de 5 - 6 miembros, heterocicloalquilo de 5 - 6 miembros (opcionalmente sustituido con uno o más alquilo C1-4) o alquilo C1-4 (opcionalmente sustituido con uno o más halo); R5 es alquilo C1-4 (opcionalmente sustituido con uno o más halo) o fenilo; y los subíndices n y m se seleccionan independientemente entre 0, 1, y 2; o una sal farmacéuticamente aceptable, o un solvato, o un solvato de las sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161434077P | 2011-01-19 | 2011-01-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR084857A1 true AR084857A1 (es) | 2013-06-26 |
Family
ID=45507689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120100129A AR084857A1 (es) | 2011-01-19 | 2012-01-13 | Derivados de azetidina utiles para el tratamiento de enfermedades metabolicas e inflamatorias |
Country Status (17)
Country | Link |
---|---|
US (2) | US8759334B2 (es) |
EP (1) | EP2665704A1 (es) |
JP (1) | JP2014507414A (es) |
KR (1) | KR20140040104A (es) |
CN (1) | CN103328442A (es) |
AR (1) | AR084857A1 (es) |
AU (1) | AU2012208693B2 (es) |
BR (1) | BR112013018286A2 (es) |
CA (1) | CA2824460A1 (es) |
CO (1) | CO6741223A2 (es) |
GB (1) | GB2489382A (es) |
MX (1) | MX2013008257A (es) |
RU (1) | RU2013138372A (es) |
SG (1) | SG191291A1 (es) |
TW (1) | TW201245144A (es) |
WO (1) | WO2012098033A1 (es) |
ZA (1) | ZA201304822B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2013138372A (ru) * | 2011-01-19 | 2015-02-27 | Галапаго Нв | Производные азетидина, применяемые для лечения метаболических и воспалительных заболеваний |
CA2929436C (en) | 2013-11-27 | 2021-06-15 | Euroscreen Sa | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases |
US9839644B2 (en) | 2014-09-09 | 2017-12-12 | ARKAY Therapeutics, LLC | Formulations and methods for treatment of metabolic syndrome |
KR101656662B1 (ko) * | 2014-11-18 | 2016-09-12 | 한국생명공학연구원 | 2-옥소-1,2,3,4-테트라하이드로피리미딘-5-카르복사미드 유도체를 유효성분으로 함유하는 대사성 질환 예방 또는 치료용 약학적 조성물 |
CA2991020A1 (en) | 2015-07-07 | 2017-01-12 | Japan Tobacco Inc. | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof |
CA3047891A1 (en) | 2016-12-21 | 2018-06-28 | Japan Tobacco Inc. | Process for preparing 7h-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof |
MY196582A (en) | 2018-02-13 | 2023-04-19 | Gilead Sciences Inc | PD-1/PD-L1 Inhibitors |
CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
CN108863980A (zh) * | 2018-07-05 | 2018-11-23 | 浙江工业大学 | 一种合成1-(5-苯并噻唑基)乙酮的方法 |
ES2962674T3 (es) | 2018-07-13 | 2024-03-20 | Gilead Sciences Inc | Inhibidores PD-1/PD-L1 |
WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
CN110684000B (zh) * | 2019-10-18 | 2021-08-31 | 上海皓元医药股份有限公司 | 苯并呋喃衍生物的制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5927869A (ja) | 1982-08-06 | 1984-02-14 | Sagami Chem Res Center | 4−オキソ−4,5,6,7−テトラヒドロインド−ルの製造方法 |
WO2006127702A2 (en) * | 2005-05-23 | 2006-11-30 | Neuren Pharmaceuticals Limited | Analogs of glycyl-prolyl-glutamate |
WO2006036688A2 (en) * | 2004-09-22 | 2006-04-06 | Arena Pharmaceuticals, Inc. | Gpr43 and modulators thereof for the treatment of metabolic-related disorders |
WO2007047408A2 (en) * | 2005-10-12 | 2007-04-26 | Pathologica, Llc. | Promac signature application |
WO2007052466A1 (ja) * | 2005-11-04 | 2007-05-10 | Eisai R & D Management Co., Ltd. | Gpr40とホスホリパーゼとを用いる疾患に有用な物質のスクリーニング方法 |
PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
WO2008135525A2 (en) | 2007-05-02 | 2008-11-13 | Boehringer Ingelheim International Gmbh | Substituted azetidines, manufacturing and use thereof as medicaments |
KR20100119576A (ko) | 2008-02-21 | 2010-11-09 | 액테리온 파마슈티칼 리미티드 | 2-아자-바이시클로[2.2.1]헵탄 유도체 |
JP2010051307A (ja) * | 2008-07-28 | 2010-03-11 | Eisai R & D Management Co Ltd | Th17細胞およびTreg細胞の分化誘導を調節する物質のスクリーニング方法 |
RU2013138372A (ru) * | 2011-01-19 | 2015-02-27 | Галапаго Нв | Производные азетидина, применяемые для лечения метаболических и воспалительных заболеваний |
-
2012
- 2012-01-10 RU RU2013138372/04A patent/RU2013138372A/ru not_active Application Discontinuation
- 2012-01-10 GB GB1213267.6A patent/GB2489382A/en not_active Withdrawn
- 2012-01-10 JP JP2013549769A patent/JP2014507414A/ja active Pending
- 2012-01-10 KR KR1020137020884A patent/KR20140040104A/ko not_active Application Discontinuation
- 2012-01-10 CN CN2012800059625A patent/CN103328442A/zh active Pending
- 2012-01-10 CA CA2824460A patent/CA2824460A1/en not_active Abandoned
- 2012-01-10 AU AU2012208693A patent/AU2012208693B2/en not_active Expired - Fee Related
- 2012-01-10 SG SG2013048038A patent/SG191291A1/en unknown
- 2012-01-10 BR BR112013018286A patent/BR112013018286A2/pt not_active IP Right Cessation
- 2012-01-10 WO PCT/EP2012/050297 patent/WO2012098033A1/en active Application Filing
- 2012-01-10 US US13/980,798 patent/US8759334B2/en not_active Expired - Fee Related
- 2012-01-10 EP EP12700552.8A patent/EP2665704A1/en not_active Withdrawn
- 2012-01-10 MX MX2013008257A patent/MX2013008257A/es not_active Application Discontinuation
- 2012-01-13 AR ARP120100129A patent/AR084857A1/es unknown
- 2012-01-18 TW TW101102008A patent/TW201245144A/zh unknown
-
2013
- 2013-06-27 ZA ZA2013/04822A patent/ZA201304822B/en unknown
- 2013-08-15 CO CO13194671A patent/CO6741223A2/es unknown
-
2014
- 2014-06-23 US US14/311,574 patent/US20140371198A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CO6741223A2 (es) | 2013-08-30 |
KR20140040104A (ko) | 2014-04-02 |
MX2013008257A (es) | 2013-08-12 |
CN103328442A (zh) | 2013-09-25 |
AU2012208693B2 (en) | 2015-02-26 |
SG191291A1 (en) | 2013-07-31 |
US8759334B2 (en) | 2014-06-24 |
EP2665704A1 (en) | 2013-11-27 |
GB201213267D0 (en) | 2012-09-05 |
JP2014507414A (ja) | 2014-03-27 |
US20140371198A1 (en) | 2014-12-18 |
GB2489382A (en) | 2012-09-26 |
CA2824460A1 (en) | 2012-07-26 |
WO2012098033A1 (en) | 2012-07-26 |
TW201245144A (en) | 2012-11-16 |
AU2012208693A1 (en) | 2013-03-21 |
ZA201304822B (en) | 2014-03-26 |
RU2013138372A (ru) | 2015-02-27 |
US20130303515A1 (en) | 2013-11-14 |
BR112013018286A2 (pt) | 2016-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR084857A1 (es) | Derivados de azetidina utiles para el tratamiento de enfermedades metabolicas e inflamatorias | |
PE20151951A1 (es) | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
AR078495A1 (es) | Compuestos policiclicos como antagonistas del receptor de acido lisofosfatidico | |
AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
AR085586A1 (es) | Derivados de acido 3-fenilpropionico ramificados y su uso como activador de sgc | |
ECSP14004812A (es) | Triazolopiridinas sustituidas | |
PE20151860A1 (es) | Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhidores de la phd | |
AR060609A1 (es) | Compuestos inhibidores de proteinquinasas c-fms. | |
CO6561783A2 (es) | Inhibidores del virus flaviviridae | |
AR094262A1 (es) | Compuestos antivirales para el tratamiento de la hepatitis c | |
AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
CR11683A (es) | Piridinas y pirazinas como inhibidores de p13k | |
CO6620055A2 (es) | Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos | |
MA37712A2 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
AR087182A1 (es) | DERIVADOS DE INDOL SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
UY33961A (es) | Compuestos de bis(fuoroalquil)-1,4-benziodiazepinona | |
BR112016010080A8 (pt) | compostos de pirazolopirimidina, composição farmacêutica e seu uso | |
AR060489A1 (es) | Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol | |
AR063119A1 (es) | Derivados de piridinonas sustituidas, composiciones farmaceuticas que los contienen y usos como antagonistas en trastornos asociados a receptores del tipo i de la hormona de melanina(mch-1 o mchr-1) | |
AR083760A1 (es) | Agentes antibacterianos y composiciones farmaceuticas | |
AR083879A1 (es) | Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos | |
AR106652A1 (es) | Compuestos para tratar la esclerosis lateral amiotrófica | |
ECSP13013011A (es) | Triazolopiridinas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |